Robert Schultz - Satsuma Pharmaceuticals Manufacturing Chemistry
| STSADelisted Stock | USD 1.10 0.01 0.90% |
Insider
Robert Schultz is Manufacturing Chemistry of Satsuma Pharmaceuticals
| Age | 59 |
| Phone | 650 410 3200 |
| Web | https://www.satsumarx.com |
Satsuma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4962) % which means that it has lost $0.4962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0404) %, meaning that it created substantial loss on money invested by shareholders. Satsuma Pharmaceuticals' management efficiency ratios could be used to measure how well Satsuma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Satsuma Pharmaceuticals currently holds 205 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Satsuma Pharmaceuticals has a current ratio of 9.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Satsuma Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jennifer Cormier | PepGen | N/A | |
| James McArthur | PepGen | 62 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| James Collins | Senti Biosciences | 58 | |
| MD MPH | MediciNova | 56 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Craig Esq | Cingulate | 51 | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Robert Lutjens | Addex Therapeutics | 56 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Jennifer Chickering | Cyclerion Therapeutics | N/A | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Nicole White | Assembly Biosciences | N/A | |
| Stephanie Yao | Kronos Bio | N/A | |
Management Performance
| Return On Equity | -1.04 | |||
| Return On Asset | -0.5 |
Satsuma Pharmaceuticals Leadership Team
Elected by the shareholders, the Satsuma Pharmaceuticals' board of directors comprises two types of representatives: Satsuma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Satsuma. The board's role is to monitor Satsuma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Satsuma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Satsuma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Schultz, Manufacturing Chemistry | ||
| Robert Janosky, Chief Officer | ||
| John MBA, CEO Pres | ||
| Detlef Albrecht, Chief Officer | ||
| Mic Iwashima, VP Operations | ||
| Thomas ONeil, Chief Officer | ||
| Shannon Strom, VP Affairs |
Satsuma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Satsuma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.04 | |||
| Return On Asset | -0.5 | |||
| Current Valuation | (35.53 M) | |||
| Shares Outstanding | 33.15 M | |||
| Shares Owned By Insiders | 10.43 % | |||
| Shares Owned By Institutions | 57.90 % | |||
| Number Of Shares Shorted | 130.12 K | |||
| Price To Earning | 22.12 X | |||
| Price To Book | 0.42 X | |||
| EBITDA | (58.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |